New drug combo shows promise for recurrent ovarian cancer in early trial

NCT ID NCT02627443

First seen Nov 17, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This early-phase trial tests whether adding an experimental drug (berzosertib) to standard chemotherapy (carboplatin and gemcitabine) is safe and effective for people with ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 participants and aims to find the best dose while monitoring side effects. It is not a cure, but may help control the disease for a longer time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida, 32610, United States

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky, 40536, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, 22908, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan, 48334, United States

Conditions

Explore the condition pages connected to this study.